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Abstract
Background: When subgroup analyses are not correctly analyzed and reported, incorrect conclusions may be
drawn, and inappropriate treatments provided. Despite the increased recognition of the importance of subgroup
analysis, little information exists regarding the prevalence, appropriateness, and study characteristics that influence
subgroup analysis. The objective of this study is to determine (1) if the use of subgroup analyses and multivariable
risk indices has increased, (2) whether statistical methodology has improved over time, and (3) which study
characteristics predict subgroup analysis.
Methods: We randomly selected randomized controlled trials (RCTs) from five high-impact general medical journals
during three time periods. Data from these articles were abstracted in duplicate using standard forms and a
standard protocol. Subgroup analysis was defined as reporting any subgroup effect. Appropriate methods for
subgroup analysis included a formal test for heterogeneity or interaction across treatment-by-covariate groups. We
used logistic regression to determine the variables significantly associated with any subgroup analysis or, among
RCTs reporting subgroup analyses, using appropriate methodology.
Results: The final sample of 416 articles reported 437 RCTs, of which 270 (62 %) reported subgroup analysis. Among
these, 185 (69 %) used appropriate methods to conduct such analyses. Subgroup analysis was reported in 62, 55, and
67 % of the articles from 2007, 2010, and 2013, respectively. The percentage using appropriate methods decreased
over the three time points from 77 % in 2007 to 63 % in 2013 (p < 0.05). Significant predictors of reporting subgroup
analysis included industry funding (OR 1.94 (95 % CI 1.17, 3.21)), sample size (OR 1.98 per quintile (1.64, 2.40), and a
significant primary outcome (OR 0.55 (0.33, 0.92)). The use of appropriate methods to conduct subgroup analysis
decreased by year (OR 0.88 (0.76, 1.00)) and was less common with industry funding (OR 0.35 (0.18, 0.70)). Only 33
(18 %) of the RCTs examined subgroup effects using a multivariable risk index.
Conclusions: While we found no significant increase in the reporting of subgroup analysis over time, our results
show a significant decrease in the reporting of subgroup analyses using appropriate methods during recent
years. Industry-sponsored trials may more commonly report subgroup analyses, but without utilizing appropriate
methods. Suboptimal reporting of subgroup effects may impact optimal physician-patient decision-making.
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Background
Heterogeneity of treatment effects (HTE) exists when
not all patients respond to a treatment in a similar fash-
ion [1]. Understanding HTE will allow providers to tar-
get treatments and provide the best guidance to patients
who are most likely to benefit. Multiple examples of
clinically important HTE have been shown in the litera-
ture [2–5], and more efficient targeting of treatment is
not only a better use of resources, but can also reduce
side effects and other adverse outcomes. However, the
only way to determine which groups of patients are most
likely to incur a net benefit is to examine treatment ef-
fects across subgroups of patients [6, 7].
Statistical methods for examining HTE across sub-
groups of patients (“subgroup analysis”) have been well
described [6–8]. These methods are included in guide-
line documents such as the CONSORT statement [9], as
well as in documented methodology standards for the
Patient-Centered Outcomes Research Institute (PCORI)
[10]. While studies have examined subgroup reporting
and methodology in general medical journals [11–16],
subspecialties [17, 18], and surgery [19], understanding
the underlying factors that influence reporting and use
of appropriate methodology has not been well explored.
Indeed, the most comprehensive study to date [13] was
limited to 1 year (2007) and did not differentiate be-
tween appropriate and inappropriate methodology for
subgroup analysis. An earlier review [16] that examined
subgroup reporting during the years 1994, 1999, and
2004 found that subgroup analysis was reported in less
than 60 % of randomized controlled trials (RCTs) and
correctly analyzed approximately half the time, although
this study did not explore the predictors of appropriate
statistical methodology. Furthermore, little research ex-
ists regarding which variables are selected for subgroup
analysis. Single variables are often the most simple to
examine but can only assess a single dimension of risk.
Recent simulations suggest it may be far preferable to
assess treatment effect heterogeneity across groups de-
fined by simultaneous dimensions of risk, via use of a
multivariable risk index, which increase power and effi-
ciency [3, 20]. However, despite known benefits to using
multivariate risk indices, the frequency of use is unknown.
This study utilizes a large sample of RCTs published in
high-impact journals to determine (1) if the use of sub-
group analyses and multivariable risk indices has in-
creased, (2) whether statistical methodology has improved




We randomly selected a sample of RCTs published dur-
ing three time periods in each of five high-impact
general medical journals. The search strategy and ab-
straction forms were developed as part of a previously
published study [16]. This study was deemed exempt
from the human subject research requirements by the
University of Pennsylvania. This study was funded by a
grant from the National Pharmaceutical Council.
Data sources and search
Using a highly sensitive search strategy [21], we searched
PubMed for RCTs published in the Annals of Internal
Medicine, British Medical Journal (BMJ), Journal of the
American Medical Association (JAMA), Lancet, and the
New England Journal of Medicine during the years 2007,
2010, 2013, and the first quarter of 2014. These five jour-
nals were selected due to their broad coverage of medical
content and substantial impact on medical research and
policy [22]. RCTs published during the first quarter of
2014 were included to provide the most recent sample
possible and are combined with the 2013 RCT cohort.
Our search yielded 2806 articles. These articles were
then randomized into ten batches of approximately 280
articles, stratified by journal and year. Batches (n = 4)
were randomly selected for assessment of inclusion cri-
teria and full abstraction until we achieved a final sample
size of a minimum of 400 included trials.
Study inclusion
Trials were eligible for inclusion in our sample if they met
the following criteria: (1) reported on a human population,
(2) reported on a parallel or crossover (including n-of-1)
randomized controlled trial, and (3) used randomization
at the individual patient level or time within patient (for
crossover trials). Nonexperimental designs were excluded,
as were cluster-randomized trials, because they often re-
port group-level effects.
Data abstraction
All studies were independently abstracted by two trained
abstracters. Any disagreements were adjudicated by a se-
nior researcher. We used a standard protocol, forms,
and electronic database [23] that collected the following
information: first author’s last name, journal of publica-
tion, year of publication, whether one of the trial authors
had formal training in biostatistics (defined as an author
holding a terminal degree in statistics, biostatistics, or a
related field), medical condition under study, first au-
thor’s region (North America, Europe, or other), funding
source (any industry funding or no industry funding),
the statistical significance of the primary outcome, study
design (parallel or crossover), sample size, number of
randomized arms, and number of participants random-
ized to each arm.
Outcomes included the following: (1) any explor-
ation of treatment effect heterogeneity (“subgroup
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analysis”); (2) among those trials that explored sub-
groups, use of appropriate statistical methodology
(“appropriate methods”); and (3) use of a multivariable
risk index to explore subgroups. Subgroup analysis
was defined as any reporting of subgroup-specific
treatment effects. Subgroup-specific treatment effects
included the use of an interaction term in a multivari-
able model, reporting stratified analyses, or reporting
of a single subgroup-specific effect (for example, the
treatment effect in women in a study that included
both men and women). Appropriate methods for sub-
group exploration included applying a test for inter-
action between the treatment assignment and one or
more covariates, or a statistical test of differences in treat-
ment effects across subgroups [6, 7]. Solely reporting
subgroup-specific effects without a statistical test for het-
erogeneity was not considered appropriate methodology.
Among the studies reporting subgroup analysis using
appropriate methods, we collected a list of the variables
examined in the subgroup analysis, including the use of
a multivariable risk index. A multivariable risk index is a
single variable (usually generated through a multiple lo-
gistic regression approach) that captures more than one
dimension of risk and allows for risk-based stratification
of multiple dimensions [3]; one example is the APACHE
score, a severity of disease classification score for critic-
ally ill patients. Variables were categorized into the fol-
lowing categories: anthropomorphics, center or site,
comorbidities at baseline, demographics, diet and phys-
ical functioning, disease severity, history (such as a prior
procedure and prior medication exposure), medication
at baseline, measures of time (such as season or year),
and multivariable risk index.
In order to plot the prevalence of reporting subgroup
analysis using appropriate methods over time, we sup-
plemented the current study’s data with those from our
prior study [16]. Inclusion of these prior data allows for
visualization of six time points over approximately 20
years (1994–2013). The assessment and definition of the
subgroup analysis and appropriate methodology was
identical to this current study, thereby allowing for com-
bination and direct comparison.
Finally, to assess whether subgroup analysis was re-
ported in a secondary publication, we conducted a
forward-citation search of articles that did not report
subgroup analysis. Articles that cited these trials were
examined to determine if they (1) reported on the
same trial participants as the article included in our
primary sample; (2) reported subgroup analysis; and
(3) if so, used appropriate methods to do so.
Statistical analysis
Data are summarized as number (percent) or median
(range) for discrete and continuous variables, respectively.
Bivariable relationships are assessed using chi-square tests.
A test for trend is used for the publication year and quin-
tile of sample size. Fisher’s exact test is used when the
sample size is small. P values of 0.05 or less were consid-
ered statistically significant.
Logistic regression analysis was used to examine (1)
predictors of subgroup exploration and (2) predictors of
using correct methodology for subgroup exploration. Po-
tential predictors include the publication year (entered
as a continuous variable), biostatistician as a coauthor,
medical condition under study, first author’s region,
funding source, the statistical significance of the trial’s
primary outcome (defined as significant vs. not signifi-
cant), and sample size (entered as continuous quintiles).
The journal of publication was included in all analyses
to control for unmeasured differences across journals.
The overall significance of predictors was measured using
the Wald test. Predicted probabilities of reporting any
subgroup analysis or using appropriate methodology to re-
port subgroup analysis was calculated using the marginal
standardization method. This method reflects a weighted
average over the distribution of confounders and allows
inference to the total population.
Post hoc, we conducted an exploratory analysis exam-
ining the potential interaction between funding source
and the overall significance of the trial’s primary out-
come because a prior study [13] indicated that the over-
all significance of the trial’s primary outcome moderated
the effect between funding and subgroup exploration.
Finally, we conducted an analysis restricted to stud-
ies reporting an overall sample size of at least 250
participants, with at least 100 randomized per arm, to
determine if similar trial characteristics were associ-
ated with subgroup reporting among trials with
greater potential for such reporting based on sample
size and distribution.
Results
Four batches of papers comprising 1123 articles
(representing 1146 studies) were randomly selected
for screening. A total of 674 articles were excluded
for having trial designs that were not randomized
controlled trials, and an additional 35 were excluded
for being cluster-randomized trials (Fig. 1). The most
common study designs that were excluded were co-
hort studies (264 (39 %)), reviews (including meta-
analysis and systematic reviews) (188 (29 %)), and
editorials/commentaries/news articles (99 (15 %)). The
437 included trials (38 % of the initial 1146 studies)
were contained in 416 articles: 19 articles reported on
more than one RCT, 17 reported on two RCTs, and
two articles reported on three RCTs. Articles could
report on an included and an excluded study.
Gabler et al. Trials  (2016) 17:320 Page 3 of 12
Among the included RCTs, the most common medical
conditions under study were cardiovascular (23 %), can-
cer (19 %), and psychiatry/neurology (14 %) (Table 1).
The majority of first authors were from either North
America (42 %) or Europe (43 %), more than half (57 %)
of the RCTs did not receive any funding from industry,
and 58 % included a biostatistician as a named coauthor.
The vast majority of the trials (97 %) had a parallel
group trial design, 64 % of the trials reported a statisti-
cally significant primary outcome analysis, and sample
size ranged from 7 to 170,432 with a median of 506 par-
ticipants. More than half (62 %; 270/437) of the included
RCTs reported some subgroup analysis. Of the 270 RCTs
reporting some subgroup analysis, 185 (69 %) used cor-
rect methodology.
The results of bivariable analyses examining the rela-
tionships between study characteristics and (1) subgroup
analysis or (2) using appropriate methods for subgroup
analysis are reported in Table 2. Briefly, the journal of
publication (p = 0.01), medical condition under study
(p = 0.003), funding (p < 0.001), significance of the pri-
mary outcome (p = 0.013), study design (p = 0.002), and
sample size (p < 0.001) were all significantly associated
with reporting any subgroup analysis. Only the year of
publication (p = 0.046), medical condition under study
(p < 0.001), funding source (p = 0.005), significance of
primary outcome (p = 0.003), and sample size (p = 0.01)
were associated with using appropriate methods to con-
duct subgroup analysis.
Among the trials reporting subgroup analysis using ap-
propriate methods, the most common variables exam-
ined were disease severity (reported in 69 % of studies),
demographics (reported in 67 % of trials), baseline co-
morbidities (31 %), and baseline medication (28 %)
(Additional file 1: Table S1). Of the studies that reported
subgroup analysis on demographics, age (87 %) and sex
(73 %) was the most common. Only 33 studies (18 %)
examined subgroups using a multivariable risk index.
Figure 2 illustrates the percentage of trials reporting
subgroup analysis using appropriate statistical methods
over time. Year (2007, 2010, and 2013) showed a signifi-
cant decrease in the bivariable and adjusted analysis, and
additionally, the inclusion of data for 1994, 1999, and 2004
[16] show that peak appropriate reporting occurred in
2007 and decreased thereafter. Reporting percentage using
appropriate methods was less than 50 % for the earlier
Fig. 1 Study search and selection flow diagram
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time points (43 % in 1994 and 48 % in 1999), increased to
77 % in 2007, and then decreased to 63 % in 2013.
In a multivariable logistic regression, we found that
trials receiving industry funding were more likely to re-
port any subgroup analysis (OR 1.94 (95 % CI 1.17,
3.21)) as were studies with a greater sample size (1.98
(1.64, 2.40) per sample size quintile), but studies with a
significant primary outcome were less likely to report
subgroup analysis (0.55 (0.33, 0.92) (Table 3). In an ana-
lysis restricted to trials reporting subgroup analysis, year
of publication, medical condition under study, and fund-
ing source were all significant predictors of using appro-
priate methods. More recent studies were less likely to
report subgroups using appropriate methods (0.88 (0.76,
1.00)), as illustrated in Fig. 2. In contrast to the analysis
predicting subgroup analysis, industry funding was asso-
ciated with reduced odds of using appropriate methods
(0.39 (0.120, 0.77)). The predicted probability for report-
ing subgroup analysis was 69 % (95 % CI 62, 75 %) for
trials that received industry funding and 56 % (51, 62 %)
for studies that did not receive industry funding, but the
probability of using appropriate methods to do so was
62 % (54 %, 69 %) for industry-funded studies and 78 %
(71, 85 %) for nonindustry funded studies (Table 4).
The use of a multivariable risk index for subgroup
analysis using appropriate methods is reported in Add-
itional file 1: Table S2. None of the baseline study char-
acteristics were significantly associated with use of a risk
index in bivariable analyses, although the sample size is
nearly significant (p = 0.06), with studies with larger
sample sizes more likely to use a risk index when com-
pared to studies with smaller sample sizes.
A sensitivity analysis restricting to trials with a sample
size of at least 250 participants and 100 participants per
randomized arm (Additional file 1: Table S3) showed
similar results to main bivariable analyses. The medical
condition under study (p = 0.004), funding source (p <
0.001), significance of the primary outcome (p = 0.015),
and sample size (p < 0.001) were all significantly associ-
ated with the reporting of subgroup analysis, while
medical condition under study (p < 0.001), funding
source (p = 0.01), and significance of the primary out-
come (p = 0.006) were significantly associated with
using correct methods for reporting subgroup analysis
Table 1 Articles and randomized controlled trials (RCTs) included






Annals 36 (9) 37 (8)
British Medical Journal 47 (11) 48 (11)
Journal of the American
Medical Association
72 (17) 76 (17)
Lancet 115 (28) 123 (28)
New England Journal of
Medicine
146 (35) 153 (35)
Year of publication
2007 113 (27) 119 (27)
2010 140 (34) 144 (33)
2013–2014 163 (39) 174 (40)











Pulmonary/critical care 29 (7)
Obstetrics/gynecological 21 (5)
Other chronic disease 41 (9)
Other, uncategorized 27 (6)
First author’s region –




Industry funding 188 (43)
No industry funding 249 (57)
Significance of the primary
outcomea
–
Not significant 153 (36)
Significant 277 (64)
Study design –






Table 1 Articles and randomized controlled trials (RCTs) included




No subgroup analysis 167 (38)
Sample size – 506 (7–170,432)
n (%) or median (range)
an = 7 trials were excluded for not reporting a statistical test for the
primary outcome
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Table 2 Bivariable associations between trial characteristics and reporting of any exploration of subgroup analysis and reporting of
subgroup analysis using appropriate methods
Characteristic Number Reports subgroup analysis,
n (%) N = 270
Uses appropriate methods,
n (%) N = 185
Journal of publication p = 0.01 p = 0.22
Annals 37 21 (57) 18 (86)
British Medical Journal 48 21 (44) 12 (57)
Journal of the American Medical Association 76 44 (58) 33 (75)
Lancet 123 76 (62) 52 (68)
New England Journal of Medicine 153 108 (71) 70 (65)
Year of publication p = 0.27 p = 0.046
2007 119 74 (62) 57 (77)
2010 144 79 (55) 54 (68)
2013–2014 174 117 (67) 74 (63)
Biostatistician as coauthor p = 0.07 p = 0.38
No biostatistician as coauthor 183 104 (57) 68 (65)
Biostatistician as coauthor 254 166 (65) 117 (70)
Medical condition under study p = 0.003 p < 0.001
Cardiovascular 101 73 (72) 63 (86)
Infectious disease 82 52 (63) 25 (48)
Cancer 59 45 (76) 24 (53)
Psychiatry/neurology 40 20 (50) 11 (55)
Autoimmune, including diabetes 37 22 (59) 15 (68)
Pulmonary/critical care 29 14 (48) 11 (79)
Obstetrics/gynecological 21 10 (48) 8 (80)
Other chronic disease 41 24 (59) 19 (79)
Other, uncategorized 27 10 (37) 9 (90)
First author’s region p = 0.14 p = 0.19
North America 185 123 (66) 84 (68)
Europe 188 113 (60) 82 (73)
Other 64 34 (53) 19 (56)
Funding p < 0.001 p = 0.005
Industry funding 188 141 (75) 86 (61)
No industry funding 249 129 (52) 99 (77)
Significance of the primary outcomea p = 0.013 p = 0.003
Not significant 153 106 (69) 85 (80)
Significant 277 158 (57) 100 (63)
Study design p = 0.002 p = 0.53)
Parallel 425 268 (63) 18 (69)
Crossover 12 2 (17) 1 (50)
Sample size p < 0.001 p = 0.01
Quintile 1 (median = 69) 88 29 (33) 13 (45)
Quintile 2 (median = 234) 87 44 (51) 30 (68)
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(Additional file 1: Table S4, appendix). As in the main
analysis, industry funding was significantly positively
associated with subgroup analysis (85 vs. 63 %) but
negatively associated with reporting subgroups using
appropriate methods (65 vs. 81 %).
No significant interaction was observed between the
funding source and the significance of the primary out-
come for reporting any subgroup analysis (p = 0.15 for
interaction) or for using appropriate methods (p = 0.59
for interaction).
In a forward citation search that included 167 RCTs not
reporting any subgroup analysis, we found that 35 RCTs
reported subgroup analysis in a future publication. Of
these, only seven (20 %) used appropriate methodology. In
total, of the 437 RCTs in our sample, 305 (70 %) reported
on some subgroup analysis, including a later publication,
and 192 (63 %) used appropriate methods to do so.
Discussion
In this large random sample of RCTs in high-impact
general medical journals, we found that roughly two
thirds of RCTs reported subgroup analysis, and roughly
two thirds of those trials used appropriate methodology
to conduct such analyses. Furthermore, we found that
the percentage of trials using appropriate methodology
has, if anything, decreased during the past decade. Fur-
thermore, we showed a relationship with industry fund-
ing and subgroup exploration and use of appropriate
methods such that industry funding increased the odds
of subgroup analysis but decreased the odds of doing so
using appropriate methods. Finally, we showed that use
of risk indices to explore subgroup is rare. Given that
higher-impact journals tend to more frequently report
subgroup analyses [13], our estimates likely represent
upper bounds for these important practices.
Table 2 Bivariable associations between trial characteristics and reporting of any exploration of subgroup analysis and reporting of
subgroup analysis using appropriate methods (Continued)
Quintile 3 (median = 507) 88 58 (66) 39 (67)
Quintile 4 (median = 1080) 87 65 (75) 48 (74)
Quintile 5 (median = 5455) 87 74 (85) 55 (74)
For articles that report on the appropriate use of methods for subgroup analysis, the denominator used is the number reporting any subgroup analysis
Chi-square tests were used for categorical variables. In the case of small cells, we used Fishers exact test. A test for trend was used for the year and sample size
an = 7 trials were excluded for not reporting a statistical test for the primary outcome
Fig. 2 Percentage of trials reporting subgroup analysis utilizing appropriate statistical methods
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In addition to building on previous work in this area
[16], this study explores a different dimension of sub-
group analysis, namely utilizing correct methodology
among those studies that choose to explore subgroups.
Using similar inclusion and coding criteria as the prior
study allows us to combine data from the earlier study
to examine subgroup reporting over time, including the
use of appropriate methodology. While the prior manu-
script showed an increase in appropriate methodological
use over time, more recent data showed a decrease.
Whether this is an artifact of the data, possibly due to
chance variation, and smaller numbers within each year,
or whether it is a true decrease, is unknown. Given the
importance of using appropriate methods and that these
methods are well documented in guidance documents
[9], monitoring this trend into the future is important to
ensure that methodology standards are not slipping.
This is the first study to report the prevalence of sub-
group exploration while acknowledging that such ana-
lyses may be reported in a secondary manuscript. Our
Table 3 Adjusted odds ratios for reporting any exploration of subgroup analysis and for reporting subgroup analysis using
appropriate methods
Condition Predict any subgroup analysis
OR (95 % CI)
Predict subgroup analysis using appropriate
methods OR (95 % CI)
Journal of publication p = 0.60 p = 0.15
British Medical Journal 1.00 1.00
Annals 1.28 (0.43, 3.82) 7.12 (0.92, 55.31)
Journal of the American Medical Association 1.34 (0.53, 3.35) 2.40 (0.63, 8.37)
Lancet 1.35 (0.60, 3.03) 3.58 (1.18, 10.88)
New England Journal of Medicine 1.90 (0.80, 4.48) 2.28 (0.73, 7.11)
Year of publication p = 0.39 p = 0.05
Year 1.04 (0.95, 1.15) 0.88 (0.76, 1.00)
Biostatistician as coauthor p = 0.90 p = 0.11
No biostatistician as coauthor 1.00 1.00
Biostatistician as coauthor 1.03 (0.63, 1.68) 1.71 (0.89, 3.30)
Medical condition under study p = 0.10 p = 0.02
Obstetrics/gynecological 1.00 1.00
Cardiovascular 2.47 (0.83, 7.35) 2.30 (0.38, 14.02)
Infectious disease 2.03 (0.61, 6.77) 0.51 (0.08, 3.07)
Cancer 3.60 (1.09, 11.84) 0.46 (0.08, 2.67)
Psychiatry/neurology 3.03 (0.87, 10.63) 0.47 (0.07, 3.08)
Autoimmune, including DM 3.53 (1.03, 12.16) 0.71 (0.10, 4.98)
Pulmonary/critical care 1.37 (0.36, 5.22) 1.88 (0.22, 15.85)
Other chronic disease 4.80 (1.41, 16.35) 1.27 (0.18, 8.85)
Other, uncategorized 1.29 (0.37, 4.45) 3.07 (0.22, 43.87)
First author’s region p = 0.65 p = 0.47
Other 1.00 1.00
North America 1.48 (0.65, 3.40) 1.51 (0.56, 4.05)
Europe 1.38 (0.63, 2.98) 1.78 (0.71, 4.44)
Funding p = 0.01 p = 0.007
No industry funding 1.00 1.00
Industry funding 1.94 (1.17, 3.21) 0.39 (0.20, 0.77)
Significance of the primary outcome p = 0.022 p = 0.19
Not significant 1.00 1.00
Significant 0.55 (0.33, 0.92) 0.64 (0.33, 1.24)
Sample size p < 0.001 p = 0.18
Quintiles 1.98 (1.64, 2.40) 1.21 (0.91, 1.61)
Model included all variables and robust error terms; DM Diabetes Mellitus
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forward search found that an additional 21 % of RCTs
reported subgroup analysis in a later publication, for a
combined estimate of 70 %. Prior estimates of subgroup
reporting have ranged from 40–65 % [11–13, 16–19, 24];
our combined estimate suggests that those prior figures
may be underestimates, but that even with this fuller




Predicted probability (subgroup analysis
using appropriate methods)
Journal of publication
British Medical Journal 0.55 (0.41, 0.69) 0.52 (0.33, 0.71)
Annals 0.57 (0.42, 0.73) 0.84 (0.63, 1.05)
Journal of the American Medical Association 0.60 (0.49, 0.70) 0.70 (0.55, 0.86)
Lancet 0.60 (0.53, 0.68) 0.76 (0.67, 0.85)
New England Journal of Medicine 0.66 (0.59, 0.73) 0.67 (0.59, 0.75)
Year of publication
2007 0.61 (0.54, 0.69) 0.77 (0.68, 0.87)
2010 0.57 (0.50, 0.64) 0.71 (0.61, 0.80)
2013–2014 0.66 (0.59, 0.72) 0.65 (0.57, 0.73)
Biostatistician as coauthor
No biostatistician as coauthor 0.61 (0.55, 0.68) 0.65 (0.56, 0.74)
Biostatistician as coauthor 0.61 (0.56, 0.70) 0.73 (0.67, 0.80)
Medical condition under study
Obstetrics/gynecological 0.43 (0.25, 0.61) 0.71 (0.42, 1.00)
Cardiovascular 0.61 (0.52, 0.70) 0.85 (0.75, 0.95)
Infectious disease 0.57 (0.46, 0.69) 0.58 (0.44, 0.73)
Cancer 0.68 (0.57, 0.78) 0.56 (0.41, 0.70)
Psychiatry/neurology 0.64 (0.51, 0.77) 0.54 (0.32, 0.76)
Autoimmune, including DM 0.69 (0.57, 0.82) 0.67 (0.46, 0.87)
Pulmonary/critical care 0.50 (0.32, 0.68) 0.83 (0.64, 1.00)
Other chronic disease 0.75 (0.65, 0.85) 0.79 (0.64, 0.95)
Other, uncategorized 0.48 (0.33, 0.64) 0.89 (0.68, 1.00)
First author’s region
Other 0.56 (0.44, 0.69) 0.63 (0.48, 0.78)
North America 0.63 (0.57, 0.69) 0.70 (0.61, 0.79)
Europe 0.62 (0.55, 0.68) 0.73 (0.65, 0.81)
Funding
No industry funding 0.56 (0.51, 0.62) 0.78 (0.71, 0.85)
Industry funding 0.69 (0.62, 0.75) 0.62 (0.54, 0.69)
Significance of the primary outcome
Not significant 0.68 (0.62, 0.75) 0.75 (0.66, 0.84)
Significant 0.58 (0.52, 0.63) 0.67 (0.61, 0.74)
Sample size
Quintile 1 0.28 (0.17, 0.38) 0.51 (0.27, 0.75)
Quintile 2 0.54 (0.44, 0.63) 0.70 (0.56, 0.84)
Quintile 3 0.67 (0.57, 0.77) 0.70 (0.58, 0.81)
Quintile 4 0.72 (0.63, 0.82) 0.75 (0.66, 0.84)
Quintile 5 0.85 (0.78, 0.93) 0.72 (0.62, 0.82)
Predicted probabilities were calculated using the marginal standardization method; DM Diabetes Mellitus
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picture of subgroup reporting, roughly one-third of trials
originally published in high-impact journals never report
subgroup effects.
In addition, our analysis found that 69 % of RCTs
reporting subgroup analysis used appropriate methods,
but our expanded search into secondary publications
found that only 20 % (7 out of 35) of RCTs that reported
subgroup analysis in secondary publications used appro-
priate methods. Whether this is a true effect or due to
selection bias and small numbers is unknown, but the
potential for substandard reporting in secondary publi-
cations (especially those in lower-tier journals) warrants
further research.
Other studies [13–15] have also examined the role of
industry funding in subgroup exploration and analysis.
Our results corroborate prior claims that industry-
sponsored RCTs report subgroup analysis more fre-
quently [13, 15]. While other studies did not examine
the appropriateness of methods across funding categor-
ies, Sun et al. [13] showed that the significance of overall
trial results affected whether or not subgroup analyses
were reported, with industry-funded RCTs more likely to
report subgroup effects if the overall treatment effect
was null. We did not find the same interaction in our
study but did find that a significant primary outcome
was associated with less frequent subgroup exploration
overall. The DISCO group [15] examined study proto-
cols and found that industry-sponsored trials planned
more subgroup analyses than nonindustry trials. Al-
though Sun et al. [14] showed no relationship between
industry and the claiming of a subgroup effect, this is a
slightly separate question from the likelihood to explore
subgroups and the methods used to do so. Industry
funded trials may be more likely to examine subgroups
due to better funding or to more appropriately target
treatments in specific groups of patients. Our finding
that industry-funded trials are less likely to use appropri-
ate statistical methods to do so could be explained by a
few possibilities. First, industry funded trials may use ap-
propriate methods, but may not report the methods in
sufficient detail to be categorized as “appropriate” in this
study. Second, these trials may report appropriate meth-
odology, but such reporting is limited to a protocol
manuscript or another separate publication. Finally, in-
dustry sponsored trials may truly be less likely to use ap-
propriate methods to conduct subgroup analyses. For
the first two cases, strict adherence to reporting guide-
lines will likely equalize any differences currently observed
across funding groups. However, if industry-sponsored tri-
als are truly less likely to use appropriate methods to
conduct subgroup analyses, these trials may require
additional scrutiny to ensure adherence to appropriate
analytic techniques. If these findings are confirmed in
future studies, then future research involving examining
a full picture of publications related to a trial as well as
qualitative interviews and surveys of the authors of a
sample of the industry and non-industry sponsored tri-
als may help determine whether this is a reporting issue
or a methodology one.
The importance of risk indices for identifying differ-
ences across subgroups [25–27] while reducing the like-
lihood of spurious effects due to multiple comparisons is
well documented [8, 27]. However, we found that less
than 20 % of the RCTs using appropriate methodology
to examine subgroups used a risk index, and that risk in-
dices only constituted 3 % of all variables examined for
subgroup analysis. One reason for this may be that vali-
dated risk indices are not available for use in all condi-
tions. However, research has shown that the number of
available multivariable risk indices is increasing every
year, at least in cardiology [28], and a recent article has
highlighted the benefits of such approaches in the field
of critical care [29]. A simulation study [30] showed that
it is possible to develop unbiased internal models to ex-
plore subgroups across dimensions of risk, which holds
promise for future baseline risk stratification in areas
where there are no existing risk indices. Given that risk
indices increase power [3] and are better able to estimate
the benefit (or harm) of an intervention across groups of
patients [2], increased research into the development
and use of risk indices remains important.
Our results should be interpreted in light of some lim-
itations. First, our random sample only included five
general medical journals, and the inclusion of other jour-
nals would have likely yielded less favorable results. Sec-
ond, possibly, the trials did conduct subgroup analyses
using appropriate methods and statistical tests but did
not report them as such. However, to impact clinical
care, subgroups must be publicly reported. Furthermore,
the DISCO group [15] found that less than one third of
the RCT protocols included planned subgroup analyses,
indicating that many analyses that did occur in our sample
(and others) were likely unplanned. Preplanning analyses
may result in the use of more appropriate techniques.
Conclusions
Our findings suggest considerable opportunity for im-
provement in the conduct and reporting of analyses of
how treatments differentially impact patient subgroups,
even among trials published in the highest-impact jour-
nals. More rigorous reporting standards for subgroup
analysis, including the use of an iterative process of ex-
ploratory followed by confirmatory analyses and en-
couragement of the use of risk indices are needed. To
maximize the return on investment in RCTs, research
sponsors and journal editors should develop policies
that encourage subgroup exploration using appropriate
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methodology. Suboptimal reporting of subgroup effects
may impact optimal physician-patient decision-making.
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and reporting of any exploration of subgroup analysis and reporting of
subgroup analysis using appropriate methods among RCTs that have a
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